Navigation Links
Onyx Pharmaceuticals to Present at the UBS Global Life Sciences Conference
Date:9/16/2010

EMERYVILLE, Calif., Sept. 16 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the UBS Global Life Sciences Conference on Wednesday, September 22, 2010 at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time).

Interested parties may access a live webcast of the presentation on our website at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to participate during the live webcast, a recorded replay of the presentation will be available within 24 hours of the completion of the presentation through October 6, 2010.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a selective proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-phar
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... -- Pomerantz LLP is investigating claims on behalf of investors ... VTAE ).  Such investors are advised to ... or 888-476-6529, ext. 237. The investigation ... directors have violated Sections 10(b) and 20(a) of the ... February 27, 2015, the Company announced that its partner ...
(Date:2/27/2015)... Securities lawyers at Dunnam & Dunnam ... (NASDAQ: SLXP ) in connection with a ... are encouraged to contact attorney Hamilton Lindley by ... upon the shareholder value of the transaction. Under terms ... $158.00 per share in cash. At least one analyst ...
(Date:2/27/2015)... 2015 Report Details   ... trends, R&D progress, and predicted revenues ,Where is the ... the commercial prospects for this market and related technologies? ... other trends to 2025, discussing data, opportunities and prospects. ... regenerative medicine : cell-based therapies that aim to ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8
...  Hanger Orthopedic Group, Inc. (NYSE: HGR ) announced ... for the quarter ended December 31, 2011, on Thursday, February ... press release announcing the results for the quarter ended December ... February 8, 2012 after the close of the market. A ...
... DIEGO, Jan. 9, 2012 Amylin Pharmaceuticals, Inc. (Nasdaq: ... 2012, with a strong focus on driving the global commercial ... at the 30th Annual J.P. Morgan Healthcare Conference in San ... highlighted steps the company is taking to prepare for the ...
Cached Medicine Technology:Hanger Orthopedic Group, Inc. Announces Fourth Quarter 2011 Earnings Release Conference Call 2Amylin Outlines Corporate Strategy to Maximize Global Value of Diabetes Franchise and Advance Key Pipeline Candidates 2Amylin Outlines Corporate Strategy to Maximize Global Value of Diabetes Franchise and Advance Key Pipeline Candidates 3Amylin Outlines Corporate Strategy to Maximize Global Value of Diabetes Franchise and Advance Key Pipeline Candidates 4
(Date:3/1/2015)... 01, 2015 A federal court ... ) scheduled to go to trial in October ... witness to provide testimony regarding the role an ... the Profemur device, Bernstein Liebhard LLP comments. According ... Northern District of Iowa on February 25th, Wright ...
(Date:3/1/2015)... 01, 2015 “ The Barrel Mill ” ... Report, which takes a look at the latest and coolest ... host of NewsWatch and a technology expert, conducted the review ... flavor to drinks. , According to Home Distillation of Alcohol, ... spirits. Well, there’s a pretty cool product that’ll help anyone ...
(Date:2/28/2015)... Heart diseases are on the rise ... urban adult population and 5 percent of rural adult ... 20-30 percent of them require specialized investigation and treatment ... vascular diseases (CVD). , A division of Indian Business ... report titled “Indian Coronary Stent Market Forecast to 2019”. ...
(Date:2/28/2015)... February 28, 2015 The Classic ... offering a new special. Throughout all of March ... , This service can help overall ... and pain. Patients may notice certain symptoms that suggest ... These symptoms include: , 1.    Pain, clicking, and popping ...
(Date:2/28/2015)... A study out of the University of ... for the treatment of a hereditary ocular condition that ... by Dr. Robert MacLaren, professor of ophthalmology at the ... Journal on January 16, 2014 , the study treated ... that mostly affects men and leads to the degeneration ...
Breaking Medicine News(10 mins):Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 3Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2
... only a few basic ways to fight viruses. A vaccine can ... invade the body//. If a virus manages to establish itself, a ... its spread. And if all else fails, a doctor may quarantine ... scientists are exploring a fundamentally different strategy to fight viruses. They ...
... Trusts have welcomed a move to bring an end to the ... ,Till now, when a health trust falls into deficit, ... debts but in addition, some money is cut off from its ... this has meant that some health trusts find it virtually impossible ...
... provide detailed information on how well a transplanted heart ... as the Allomap test, is currently used to detect ... invasive heart muscle biopsies, but has now been shown ... the heart before pumping, and the electrical properties of ...
... the popular anti-clotting drug clopidogrel (Plavix) when taken along with ... adverse bleeding event.// ,The study, to be ... Session on March 27 at 9 am (abstract 1027-18), found ... worsen bleeding after off-pump heart bypass surgery. ...
... children, yet the number of pediatric orthopedists trained to ... decreasing nationwide. The management of fractures in children is ... is needed to provide the best care for these ... for Special Surgery (HSS). ,Fractures in ...
... of Indian MPs has come together to launch a fight ... start a massive awareness drive and also seeking a special ... that at least two people die of the infectious disease ... have decided to form a group next month and to ...
Cached Medicine News:Health News:Scientists Explore Ways to Lure Viruses to Their Death 2Health News:Scientists Explore Ways to Lure Viruses to Their Death 3Health News:Double-penalty System for Bankrupt Health Trusts Lifted 2Health News:Gene Test Shown to Measure Heart Function After Transplant 2Health News:Plavix Safe During and After Heart Bypass 2Health News:Number of Specialists Best at Treating Children's Fractures Decreasing 2Health News:Number of Specialists Best at Treating Children's Fractures Decreasing 3Health News:Indian Parliamentarians Join to Fight Against TB 2
Each handle is designed to fit a specific trephine size....
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products: